Skip to main content
SpringerLink
Log in

Cost-Effectiveness Guidelines

The Experience of Australian Manufacturers

  • Guest Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Parry TG, Thwaites RMA. The pharmaceutical industry in Australia: a benchmark study. Sydney: Australian Pharmaceutical Manufacturers Association, 1988

    Google Scholar 

  2. Johnston MA. Australia’s pharmaceutical pricing strategy [thesis]. Cambridge (MA): Harvard University, 1990

    Google Scholar 

  3. Freund D, moderator. Debate: ‘this house believes that pharmacoeconomic analysis should be mandated by governments rather than left to market forces’. PharmacoEconomics 1994; 6 (4): 352–357

    Google Scholar 

  4. Henry D. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992; 1: 54–67

    Article  PubMed  CAS  Google Scholar 

  5. Drummond M. The emerging government requirement for economic evaluation of pharmaceuticals. PharmacoEconomics 1994; 6 Suppl. 1: 42–50

    Article  PubMed  Google Scholar 

  6. National Economic Research Associates (NERA). Financing health care with particular reference to medicines. The economics of health care reform: a prototype. Vol. 2. New York: NERA, 1993

    Google Scholar 

  7. Aaron HJ. Choosing from the health care reform menu. J Am Health Policy 1991 Nov/Dec; 1 (3): 23–27

    PubMed  CAS  Google Scholar 

  8. Drummond M. Basing prescription drug payments on economic analysis: the case of Australia. Health Affairs 1992 Winter; 192 6

    Google Scholar 

  9. Drummond M. Australian guidelines for cost effectiveness studies of pharmaceuticals: the thin end of the boomerang? PharmacoEconomics 1992; 1 Suppl. 1: 61–69

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pfizer Pty Ltd, 38-42 Wharf Road, West Ryde, New South Wales, 2076, Australia

    Peter Gorham

  2. Health Economics Subcommittee of the Australian Pharmaceutical Manufacturers Association, North Sydney, New South Wales, Australia

    Peter Gorham

Authors
  1. Peter Gorham
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Reprints: Mendel Grobler, Australian Phannaceutical Manufacturers Association, 77 Berry Street, North Sydney, NSW 2060, Australia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gorham, P. Cost-Effectiveness Guidelines. Pharmacoeconomics 8, 369–373 (1995). https://doi.org/10.2165/00019053-199508050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199508050-00001

Search

Navigation